Fom Technologies A/S
CCPH:FOM1.83
DKK
-0.05
(-2.92%)
ISIN
DK0061278199
Return %
Stock
S&P 500
1Y
-63.69
14.20
3Y
-94.22
81.12
5Y
-95.81
68.34
Capital Structure
DKK
•
in mil. unless spec.Working Capital
DKK
•
in mil. unless spec.Growth Rates
DKK
•
in mil. unless spec.Semi-annual Revenue
DKK
•
in mil. unless spec.Semi-annual Earnings Per Share
DKK
•
in mil. unless spec.Semi-annual Dividends Per Share
DKK
•
in mil. unless spec.Company Description
- CEO
- Michael Henrik Stadi
- Full Time Employees
- 26
- Sector
- Producer manufacturing
- Industry
- Industrial machinery
- Address
- Bryggergården 2-12 Kastrup CR Denmark 2770
- IPO Date
- Jun 26, 2020
- Website
- fomtechnologies.com
- Similar Companies
- Business
- FOM Technologies A/S is a Danish medtech company that develops and manufactures innovative medical devices focused on improving patient outcomes in the fields of wound care, oncology, and gynecology. The company offers core products including the FDA-cleared FOM WounCell, a bio-electric cell therapy device utilizing a proprietary bio-electric field technology to accelerate chronic wound healing by stimulating cellular regeneration and reducing inflammation; the FOM OncoBalance, a non-invasive device for cancer treatment support that modulates tumor microenvironments; and the FOM GynoBalance, designed for gynecological applications to promote tissue repair and alleviate symptoms in conditions such as endometriosis. These products are delivered through disposable treatment modules paired with reusable control units, enabling precise, targeted therapies in clinical and home settings. FOM Technologies operates primarily in Europe and the United States, targeting healthcare providers, hospitals, clinics, and patients with chronic conditions. Founded in 2019 and headquartered in Copenhagen, Denmark, the company serves the medtech sector with a focus on regenerative medicine and bio-electric therapies, emphasizing evidence-based solutions backed by clinical trials and regulatory approvals including CE marking in Europe and FDA clearance in the US. Its business model centers on B2B sales to medical professionals and partnerships with distributors for global market penetration, with no reported subsidiaries or parent company affiliations. In recent developments, FOM Technologies secured a significant Series B funding round in 2024 exceeding DKK 100 million to fuel commercialization and R&D expansion following FDA clearance for WounCell. The company announced strategic partnerships in 2025 with leading US wound care centers for clinical adoption and launched pilot programs in Europe to integrate its devices into national healthcare systems. Additionally, FOM expanded its manufacturing capacity in Denmark amid growing demand and initiated preparations for further product pipeline advancements, including next-generation oncology devices.